

# ***Michael John Petruso, MD, FACP***

---

## Office Addresses:

Internal Medicine Associates  
3006 South Maryland Parkway, Suite 400  
Las Vegas, Nevada 89109  
Office- (702) 369-5582  
Fax- (702) 384-1784

Nevada Access to Research and Education Society  
Nevada AIDS Research and Education Society  
2300 South Rancho Drive, Suite 203  
Las Vegas, Nevada 89102  
Office- (702) 384-9101  
Fax- (702) 384-9109  
E-mail- [nares2lv@aol.com](mailto:nares2lv@aol.com)

## **EDUCATION AND TRAINING**

1975– 1979	Bachelor of Arts University of Nevada Las Vegas, Nevada
1984 - 1988	Medical School, Doctor of Medicine University of Nevada Reno, Nevada
1988 – 1989	Internship University of Nevada School of Medicine Reno, Nevada
1989 – 1991	Residency University of Nevada School of Medicine Las Vegas, Nevada

## LICENSES

1989 – Present Nevada Medical License #6283

## CERTIFICATIONS

National Board of Medical Examiners  
#352584

Board Certified, American Board of Internal  
Medicine Diplomate  
#139621

Fellow, American College of Physicians

## EMPLOYMENT HISTORY

2001 – Present Nevada Access to Research and Education Society  
Nevada AIDS Research and Education Society  
2300 S. Rancho Drive, Suite 203  
Las Vegas, NV 89102

1997 – 1999 Nevada Clinical Research / Co-Director  
2020 Goldring, Suite 206  
Las Vegas, NV 89102

1994 – Present Internal Medicine Associates  
3006 S. Maryland Parkway, Suite 400  
Las Vegas, NV 89109

1991 – 1994 Aspen Medical Center  
3006 S. Maryland Parkway, Suite 315  
Las Vegas, NV 89109

## HOSPITAL STAFF AFFILIATIONS

Sunrise Hospital and Medical Center	Las Vegas, NV
Desert Springs Hospital	Las Vegas, NV
Valley Hospital and Medical Center	Las Vegas, NV
Mountain View Hospital	Las Vegas, NV
Summerlin Hospital	Las Vegas, NV
Southern Hills Hospital	Las Vegas, NV

## **ACADEMIC APPOINTMENTS**

June 1991 – Present	Clinical Associate Professor Department of Internal Medicine University of Nevada School of Medicine Reno, Nevada
---------------------	--

## **PROFESSIONAL APPOINTMENTS**

1994 – 1995	Director, Utilization Review Committee Nevada Health Visions Amicus Medical Las Vegas, Nevada
1994 – 1995	Quality Assurance Committee Sunrise Hospital and Medical Center Las Vegas, Nevada
1995 – 1997	Chief of General Internal Medicine Sunrise Hospital and Medical Center Las Vegas, Nevada
1996 – 1998	Chief, Department of Internal Medicine Mountain View Hospital Las Vegas, Nevada
1997 – 1999	Vice Chief, Internal Medicine Sunrise Hospital and Medical Center Las Vegas, Nevada
1998 – 1999	Chairman, Physician Advisory Committee Sunrise Hospital and Medical Center Las Vegas, Nevada
1998 – 1999	Medical Director Valley Home Health Las Vegas, Nevada
2001 – 2002	Co-Chairman, Pharmacy Safety Committee Sunrise Hospital and Medical Center

Las Vegas, Nevada

2005 – Present  
Chief, Department of Internal Medicine  
Sunrise Hospital and Medical Center  
Las Vegas, Nevada

## **COMMUNITY ORGANIZATIONS AND AWARDS**

1995  
Recognition for Participation as an Active Teacher  
In Family Practice  
American Academy of Family Physicians

1998  
Best Doctors of Las Vegas  
Las Vegas Review Journal

2000  
Best Doctors of Las Vegas  
Best Internist in Las Vegas  
Las Vegas Life Magazine

2002  
Best Doctors of Las Vegas  
Best Internist in Las Vegas  
Las Vegas Life Magazine

2004  
Best Doctors of Las Vegas  
Best Internist in Las Vegas  
Las Vegas Life Magazine

2005  
Top Doc  
Top rated Internist / Rated #2 out of top 101  
Physicians of all specialties  
215 South Magazine

## **MEMBERSHIPS AND ASSOCIATIONS**

American College of Physicians  
American Medical Association  
Nevada State Medical Society  
Clark County Medical Society

## **RESEARCH**

9188US/0017. Accept-Acolate. An open label, noncomparative, multicenter trial to evaluate acolate in patients with asthma. 1997. Investigator.

D97-019. Metrifonate to evaluate the safety and tolerability of metrifonate in patients with dementia of the alzheimer's type of mild to moderate severity. Treated with metrifonate compared to standard care for 26 weeks. Bayer. 1997. Investigator.

## **RESEARCH**

137-122. A double-blind, placebo-controlled, multicenter, phase III study to evaluate the effects of Pramlintide (AC137) on glycemic control as determined by glycosylated hemoglobin in patients with type II diabetes mellitus. Amylin. 1997. Investigator.

MA-97-0101. An open-label, community based clinical practice study of niaspan in patients with hyperlipidemia. Kos Pharmaceuticals. 1997. Investigator.

147. A double-blind, randomized, placebo-controlled study to evaluate the renal protective effects of losartan in patients with non-insulin dependent diabetes mellitus and nephropathy. Merck. 1997. Investigator.

GFXA4003. A randomized, double-blind multicenter comparison of the efficacy and safety of grepafloxacin (Raxar) 400mg or 600mg once daily and clarithromycin (Biaxin) 500mg twice daily in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. Glaxo Wellcome. 1998. Investigator.

066-0700. Eradication of helicobacter pylori infection and the treatment of active peptic ulcer disease. Pfizer. 1998. Investigator.

066-0701. Eradication of helicobacter pylori infection in patients with a history of healed peptic ulcer disease. Pfizer. 1998. Investigator.

N49-96-02-029. A multicenter, double-blind, placebo-controlled, comparison of the analgesic activity of SC-58635 100mg, SC-58635 200mg, propoxyphene napsylate 100mg with acetaminophen 650mg and placebo with remedication allowable in post-general surgical patients. Searle. 1998. Investigator.

N49-97-02-071. A multicenter, double-blind, parallel group study comparing the incidence of gastroduodenal ulcer associated with SC-58635 200mg bid with that of diclofenac 75mg bid and ibuprofen 800mg tid taken for 12 weeks in patients with osteoarthritis or rheumatoid arthritis. Searle. 1998. Investigator.

TH97-0110. A multicenter, randomized, double-blind, parallel study comparing the efficacy and safety of tramadol hydrochloride controlled-release tablets versus ultram versus placebo in patients with chronic back pain. Purdue. 1998. Investigator.

TH97-0111. A multicenter, randomized, double-blind, parallel study comparing the efficacy and safety of tramadol hydrochloride controlled-release tablets versus ultram versus placebo in patients with chronic pain due to osteoarthritis of the knee. Purdue. 1998. Investigator.

## RESEARCH

N49-98-02-082. A single dose, double-blind, placebo-controlled comparison of the analgesic activity of SC-58635 200mg, hydrocodone 10mg/acetaminophen 100mg and placebo in postorthopedic surgical patients (total hip and knee replacement surgery). Searle. 1998. Investigator.

N49-98-02-086. A double-blind, placebo-controlled, single dose and active controlled multiple dose assessment of the analgesic activity of SC-58635 200mg, hydrocodone 10mg/acetaminophen 100mg and placebo in postorthopedic surgical patients (general orthopedic surgery). Searle. 1998. Investigator.

N49-98-02-087. Clinical protocol for a multicenter, double-blind, placebo-controlled comparison study of the efficacy of SC-58635 200mg qd versus SC-58635 100mg bid in treating the signs and symptoms of osteoarthritis of the knee. Searle. 1998. Investigator.

Merck 193. A multicenter, randomized, double-blind, safety and efficacy study of H199/18 with amoxicillin plus clarithromycin compared to H199/18 for the eradication of helicobacter pylori in subjects with active duodenal ulcer or history of duodenal ulcer disease. Merck. 1998. Investigator.

068-01. A two-part, double-blind, randomized, multi-center, parallel-group 52 week study to assess the safety and tolerability and to further define the clinically effective dose range of MK-0966 in patients with rheumatoid arthritis. Merck. 1998. Investigator.

0900-00. A randomized, placebo controlled, parallel group, double-blind study to evaluate the efficacy and safety of MK-0966 12.5mg vs nabumetone 1000mg in patients with osteoarthritis of the knee. Merck. 1998. Investigator.

CV-131-127. An open label, practice based, multicenter trial with a four week treatment period intended to examine the safety and effectiveness of avapro 150mg administered once daily in subjects with hypertension. Bristol-Myers Squibb. 1998. Investigator.

N49-97-02-062. A multicenter, double-blind, parallel group study comparing the incidence of gastroduodenal ulcer associated with SC-58635 200mg bid with that of naproxen 500mg bid taken for 12 weeks in patients with osteoarthritis or rheumatoid arthritis. Searle. 1998. Investigator.

5621A-PRT014. A multicenter, evaluator-blind, three arm study of the safety and efficacy of bucladesine sodium ointment (DT-5621) in the treatment of patients with stage III pressure ulcers, including those patients with spinal cord injuries. Daiichi. 1998. Investigator.

## **RESEARCH**

MK-0966. An active comparator and placebo controlled, parallel group, 6 week, double-blind study, conducted under in-house blinding to assess the efficacy, safety and tolerability of MK-0966 in patients aged 80 and over with osteoarthritis of the knee or hip (with extensions up to 124 weeks). Merck. 1998. Investigator. (Sponsor Terminated)

TH97-0903. A multicenter, open-label study evaluating the safety and tolerability of tramadol hydrochloride controlled-released tablets in patients with chronic pain. Purdue Pharma. 1998. Investigator. (Sponsor Terminated)

M98-826. A randomized, double-blind, placebo-controlled, comparison of the safety and efficacy of ABT-594 and ibuprofen to placebo in patients with pain associated with osteoarthritis of the knee. Abbott. 1998. Investigator.

C0401-009. A phase II, randomized, placebo-controlled, dose-finding, double-blind, study of sustained release encapsulated morphine (C0401) administered epidurally for the treatment of post-operative pain in patients undergoing hip arthroplasty procedures. Depotec Corporation. 1998. Investigator.

BI527.16. A forty five day, open-label study of symptomatic relief effects of flomax capsules 0.4mg daily in patients with the signs and symptoms of benign prostatic hyperplasia. Boehringer Ingelheim. 1998. Investigator.

018-00. A 1 year, randomized, placebo and active comparator-controlled, parallel-group, double-blind, two-party study to assess the safety and efficacy of MK-0663 versus naproxen in patients with osteoarthritis. Merck. 1998. Investigator.

N49-96-02-024. Protocol to evaluate the long-term safety of SC-58635 in treating the signs and symptoms of osteoarthritis and rheumatoid arthritis. Searle. 1998. Investigator.

14777/259. A randomized, double-blind, placebo-controlled study to compare the effects of nabumetone 2gm, celecoxib 400mg and ibuprofen 2400mg per day on blood pressure control in patients with hypertension stabilized on antihypertensive therapy. SmithKline Beecham. 1998. Investigator.

49774-008. Morphine with dextromethorphan versus morphine in chronic cancer and other chronic pain (with open label extensions). Algos. 1998. Investigator.

NN2-95-02-355. A double-blind, placebo controlled, comparative study of the efficacy and upper gastrointestinal safety of arthrotec 75mg bid, nabumetone 1500mg qd and naproxen 500mg bid in treating the signs and symptoms of osteoarthritis. Searle. 1998. Investigator.

## **RESEARCH**

N49-98-01-102. A multicenter, double-blind, parallel group study comparing the incidence of clinically significant upper gastrointestinal adverse events associated with SC-58635 400mg bid to that of diclofenac 75mg bid in patients with osteoarthritis or rheumatoid arthritis. Searle. 1998. Investigator.

007. A placebo-controlled, parallel-group, double-blind study to assess safety and to define the clinically effective dose range of L-791,456 in patients with osteoarthritis of the knee followed by a double-blind, active comparator-controlled extensions (3 current extensions). Merck. 1998. Investigator.

088-00. A double-blind, randomized, stratified, parallel-group study to assess the incidence of PUB's during chronic treatment with MK-0966 or naproxen in patients with rheumatoid arthritis. Merck. 1998. Investigator.

N91-99-12-048. Revised clinical protocol for multicenter, double-blind, placebo-controlled, parallel group study comparing the incidence of gastroduodenal ulcer associated with valdecoxib 10 and 20mg qd with that of ibuprofen 800mg tid and diclofenac sodium 75mg bide taken for 12 weeks in patients with osteoarthritis. Searle. 1998. Investigator.

CVAL 489 0108. A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction. Novartis. 1999. Investigator.

991-107-006. A 6 month, double-blind, placebo-controlled, multicenter study of troglitazone (CI-911) in patients with type 2 diabetes and congestive heart failure. Parke-Davis. 1999. Investigator.

Prospective observational study of simvastatin and other statins in high risk patients. Merck. 1999. Investigator.

CVAL489 US05. An assessment of the tolerability and effectiveness of DIOVAN 80mg in subjects with hypertension in a practice-based setting. Novartis. 1999. Investigator.

Advantage 102-00. A randomized, double blind, multicenter study to evaluate the tolerability and effectiveness of rofecoxib (MK-0966) 25mg 1d vs. naproxen

500mg bid in patients with osteoarthritis. Merck. 1999. Investigator.

## RESEARCH

PPA30001. A multicenter, randomized, double-blind, double-dummy, parallel-group, glyburide-controlled, 12-month clinical evaluation of oral GI262570 7.5mg alone, micronized glyburide 12mg alone, or micronized glyburide 12mg in combination with GI262570 (2.5mg, 5mg, or 7.5mg) administered to subjects with type 2 diabetes mellitus. Glaxo Wellcome. 1999. Investigator.

024-00. An active-comparator and placebo-controlled, parallel-group, double-blind, 52 week study to assess the safety and efficacy of MK-0663 in rheumatoid arthritis patients. Merck. 1999. Investigator.

NN210005. A phase I, multicenter, randomized, parallel, double-blinded dose ranging, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral dosage regimens of GW695634G monotherapy versus placebo over 7 days in NNRTI-experienced HIV-1 infected adults. GlaxoSmithKline. 2004. Investigator.

4522US/0011. A randomized, double-blind, placebo-controlled, multicenter, phase III study of Rosuvastatin (Crestor) 20 mg in the primary prevention of cardiovascular events among subjects with low levels of LDL-Cholesterol and elevated levels of C-reactive protein. AstraZeneca. Investigator. July 2004.

CCR102881. A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naïve adults. GlaxoSmithKline. Investigator. March 2005.

CCR104627. A screening protocol to determine eligibility for one of three Phase III treatment studies evaluating the efficacy and safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 infected, treatment-experienced subject with drug-resistant virus or an observational study in X4-tropic or non-phenotypeable HIV-1 infected, treatment-experienced subjects with drug-resistance virus. GlaxoSmithKline. Investigator. July 2005.

U10-04-02-007. A randomized, double-blind, placebo-controlled, multicenter, pilot study to evaluate the safety and analgesic activity of M40403 co-

administered with an opioid agent in a cancer pain model. Metaphore Pharmaceuticals. Investigator. July 2005.

## **RESEARCH**

CVAH631BUS04/A. A 28 week, multicenter, randomized, active controlled, parallel group study to evaluate the effects of Diovan HCT (160/12.5 mg) in comparison with hydrochlorothiazide (25 mg) monotherapy, for the treatment of patients with hypertension, uncontrolled by hydrochlorothiazide (12.5 mg) monotherapy. Novartis. Investigator. August 2005.

CSPP100A2328. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study comparing an eight week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis. Investigator. August 2005.

HPR20001. A phase IIb, randomized, multicenter, parallel group study to evaluate the short-term safety, pharmacokinetics and antiviral activity of four blinded dosing regimens of GW640385/ritonavir therapy compared to open-label current protease inhibitor therapy in HIV-1 infected, protease inhibitor experienced adults for 2 weeks with long-term evaluation (>48 weeks) of safety, pharmacokinetic and antiviral activity of selected GW640385/ritonavir dosing regimen(s) vs. a ritonavir-boosted, protease inhibitor containing regimen. GlaxoSmithKline. Investigator. October 2005.

TMC114-C211. A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. ARTEMIS TRIAL. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

TMC114-C226. Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

M05-750. A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of fenofibric acid and atorvastatin calcium combination therapy to fenofibric acid and atorvastatin calcium monotherapy in subjects with mixed dyslipidemia. Abbott Laboratories. Investigator. December 2005.

M05-758. A long-term, open-label, safety extension study of the combination of fenofibric acid and statin therapy for subjects with mixed dyslipidemia. Abbott Laboratories. Investigator. December 2005.

## **RESEARCH**

D5899C00001. A 12 month double-blind, double-dummy, randomized parallel group, multicenter efficacy and safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg bid and 2 x 80/4.5 mcg bid compared to Formoterol TBH 2 x 4.5 mcg bid and placebo in patients with COPD. AstraZeneca. Investigator. March 2006.

References available by request.